Enlivex Therapeutics Ltd.

ENLV

$1.25

-2.34%

2026-09-02 16:00:01 EDT-$0.03

Healthcare

Biotechnology

NASDAQ

Active Trading

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming ...

Price Action of ENLV

$1.25

-2.34%-$0.03

High—

Low—

52W High-93.7%

Rel. vol—

Interval

Range5.1h

Volume—SMA5SMA10

—

Enlivex Therapeutics Ltd. (ENLV) is an Israel-based clinical-stage biotech focused on “macrophage reprogramming” as an immunotherapy approach. The company’s central therapeutic platform is designed to modulate immune cells—specifically macrophages—toward a disease-relevant functional state, with the goal of improving outcomes in inflammatory and life-threatening conditions. Business and strategy: The company’s strategy ...Enlivex Therapeutics Ltd. (ENLV) is an Israel-based clinical-stage biotech focused on “macrophage reprogramming” as an immunotherapy approach. The company’s central therapeutic platform is designed to modulate immune cells—specifically macrophages—toward a disease-relevant functional state, with the goal of improving outcomes in inflammatory and life-threatening conditions. Business and strategy: The company’s strategy centers on advancing Allocetra, an off-the-shelf, cell-based therapeutic intended to address the downstream consequences of systemic inflammation. According to the company description, Allocetra is currently in Phase II clinical evaluation for treating organ dysfunction and failure arising from sepsis. This positioning reflects a focus on high-need indications where immune dysregulation plays a central role. Products and pipeline orientation: Allocetra is the flagship product candidate. Beyond sepsis, Enlivex has also indicated that Allocetra is under preclinical investigation for potential use in solid tumor therapy. This suggests an intended broader immuno-oncology and inflammation-related application set, leveraging the same underlying macrophage reprogramming mechanism across multiple disease areas. Cost and operations perspective: As a clinical-stage biotechnology company, Enlivex’s operating profile is typically characterized by research and development spend, clinical trial costs, manufacturing scale-up requirements, regulatory pathway execution, and ongoing translational science. Public financial-modeling snapshots (e.g., enterprise value and profitability ratios) reflect that the company is not yet in a sustained revenue-generating phase at scale; instead, valuation metrics and operating cash flow measures are consistent with early-stage commercialization expectations and trial-driven progress. BOM/manufacturing considerations: For an “off-the-shelf” cell therapy approach, cost of goods generally depends on development and process economics for sourcing, manufacturing, cryopreservation/handling, quality control, and release testing. While specific BOM figures are not provided here, such therapies commonly face meaningful per-patient manufacturing and logistics costs that can heavily influence gross margin once trials mature into commercialization. Key people: Dr. Oren Hershkovitz serves as CEO (since 2019). The company is associated with scientific leadership from founders/advisors such as Prof. Dror Mevorach (identified as founder and scientific advisor in the provided materials). Wishes/near-term focus: Given its Phase II status for sepsis-related organ dysfunction and failure, the primary near-term “wish” is typically successful clinical execution—demonstrating safety, efficacy signals, and a clear regulatory and commercial path. For longer-term ambition, the company’s continued expansion into additional therapeutic areas (e.g., solid tumors) depends on preclinical results and future trial design decisions.ExpandCollapse

Founded

2005

Employees

CEO

Oren Hershkovitz

Full Name

Enlivex Therapeutics Ltd.

Sector

Healthcare

Industry

Biotechnology

ROE

248.08%

Market Cap

$0.02B

Current Ratio

193.24

WACC

10.20%

ROIC

-0.48%

Contact Information

https://www.enlivex.com

972 8 662 3301

14 Einstein Street, Ness Ziona, TA 7403618

Key Metrics of ENLV

Snapshot

Latest / TTM · 6 periods

Market Cap

$21.04M

ROCE

-0.6%

EV / EBITDA

-1.27x

-0.0% YoY

FCF Yield

-56.8%

-24.2% YoY

Cash Conversion Cycle

-4186.5d

Current Ratio

193.24

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of ENLV

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

0.00x

n/a

Debt / Equity

0.00

n/a

Current Ratio

193.24

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of ENLV

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.28 · Revenue $0.00 · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-1.15 · Revenue $0.00 · 1 analysts
Mar 31, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.12 · Revenue $0.00 · 1 analysts
Jun 30, 2027
Q2 FY2027 · Estimated results
Est. EPS $-0.08 · Revenue $0.00 · 1 analysts

Recent history

Dec 31, 2025
FY2025 · Annual results
EPS $382.20 · Revenue $0.00
Sep 30, 2025
Q3 FY2025 · Results reported
EPS $-1.38 · Revenue $0.00
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $-1.17 · Revenue $0.00
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-2.40 · Revenue $0.00
Dec 31, 2024
FY2024 · Annual results
EPS $-10.95 · Revenue $0.00
Sep 30, 2024
Q3 FY2024 · Results reported
EPS $-1.80 · Revenue $0.00

Financial Statements of ENLV

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$1.2B	+8329.2%	+56474.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-10.5M	+20.0%	-25.5%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	-98.5%	-99.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	193.24x	+2724.2%	+2903.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$2.3B	+8304.7%	+11013.8%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	382.20 vs -5.92	+6550.6%	386.85 vs -0.28	+138260.7%
Revenue Surprise	—	—	—	—

Insider Transactions of ENLV

Acquisitions (A)

Since Mar 18, 2026

Disposals (D)

Since Mar 18, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Mar 18, 2026	Hershkovitz Oren	officer: Chief Executive Officer	Ordinary Shares, par value NIS 0.40 per share	—	0	—
Mar 18, 2026	Shlosberger Shachar	officer: Chief Financial Officer	Ordinary Shares, par value NIS 0.40 per share	—	0	—
Mar 18, 2026	Hart Gili	director	Ordinary Shares, par value NIS 0.40 per share	—	0	—
Mar 18, 2026	Hart Gili	director	Option (right to buy)	—	3,382	$5.34
Mar 18, 2026	NOVIK SHAI A	director	Ordinary Shares, par value NIS 0.40 per share	—	0	—

Leadership Team of ENLV

7 executives

Name	Title	Compensation	Gender	Year Born	Status
Shai Novik	Executive Chairman	USD 528,000	Male	1966	Active
Oren Hershkovitz	Chief Executive Officer	USD 273,600	—	1977	Active
Dror Mevorach	Founder and Scientific Advisor	USD 180,000	—	1956	Active
Shachar Shlosberger	Chief Financial Officer	USD 126,000	Female	1977	Active
Einat Galamidi	Chief Medical Officer	—	—	1974	Active
Veronique Amor-Baroukh	Chief Operating Officer	—	Male	—	Active
Sigal Arad	Director of Human Resources	—	Female	—	Active

Recent News of ENLV

Zacks Investment Research3 days agoNeutral

Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Enlivex Ltd. (ENLV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

Defense World8/21/2026Neutral

Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Insider and Institutional Ownership 1.0% of Enlivex

GlobeNewsWire7/30/2026Neutral

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics.

GlobeNewsWire7/29/2026Neutral

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time to provide investors with additional detail on the Company's recently announced private placement (the “Transaction”), the status and strategy of its RAIN treasury, and recent clinical progress for Allocetra™.

GlobeNewsWire7/28/2026Neutral

Enlivex Announces $400,000,000 Private Placement

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) at a price of $5.00 per share for subscription amounts funded in U.S. dollars, USDT or USD Coin and $6.00 per share for subscription amounts funded in RAIN tokens, the $5.00 price representing a premium of 17.4% and the $6.00 price representing a premium of 40.8%, in each case to the closing price of the ordinary shares on July 27, 2026, for expected aggregate gross proceeds of approximately $400,000,000 (funded in U.S. dollars, USDT, USD Coin, RAIN tokens or a combination thereof), before deducting offering expenses (the "Transaction"). The investor has elected to fund the purchase price using RAIN tokens, which election may be changed at any time prior to closing. Enlivex intends to use net proceeds from the private placement in furtherance of its treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum, while continuing to advance Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis.

Historical Employee Count of ENLV

Current

Change

-5.56%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	34	20-F	Mar 25, 2026	View
Dec 31, 2024	36	20-F	Apr 30, 2025	View
Dec 31, 2023	49	20-F	Apr 30, 2024	View
Dec 31, 2022	77	20-F	Apr 10, 2023	View
Dec 31, 2021	71	20-F	Apr 29, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Enlivex Therapeutics Ltd.